CCM
FTH

Catalio Capital Management’s Faeth Therapeutics FTH Stock Holding History

Catalio Capital Management’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$368K Hold
14,718
– – 0.07% 39
2026
Q1 		$464K Hold
14,718
– – 0.1% 40
2025
Q4 		$157K Hold
14,718
– – 0.03% 45
2025
Q3 		$139K Hold
14,718
– – 0.03% 38
2025
Q2 		$126K Sell
14,718
-1
-0% -$7 0.03% 40
2025
Q1 		$116K Hold
14,719
– – 0.03% 37
2024
Q4 		$144K Buy
+14,719
New +$148K 0.03% 33

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Catalio Capital Management's FTH Position: Q2 2026 in Review

Catalio Capital Management held its Faeth Therapeutics (FTH) position steady in Q2 2026 at 14,718 shares worth $368K. The position accounts for 0.07% of the portfolio, ranked #39.

Catalio Capital Management first reported a position in FTH in Q4 2024 and has held it in 7 quarters since. The position peaked at $464K in Q1 2026. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Catalio Capital Management held 14,718 shares of Faeth Therapeutics worth $368K as of Q2 2026.
  • Catalio Capital Management left its Faeth Therapeutics share count unchanged in Q2 2026.
  • Faeth Therapeutics made up 0.07% of Catalio Capital Management's portfolio in Q2 2026, its #39 holding.
  • Catalio Capital Management first reported a position in Faeth Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Catalio Capital Management's Faeth Therapeutics position peaked at $464K in Q1 2026.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.